Healthcare utilization and costs for patients with Parkinson’s disease in Taiwan
Abstract Background Parkinson’s disease (PD) exerts a considerable burden on the elderly. Studies on long-term costs for Parkinson’s disease patients in Taiwan are not available. Objectives This study aims to examine the medical resource utilization and medical costs including drug costs for PD pati...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Neurology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12883-024-03988-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841559395344842752 |
|---|---|
| author | Kuan-Chen Chen Li-Jung Elizabeth Ku Ya-Hui Hu Yu Sun Alexis Elbaz Pei-Chen Lee |
| author_facet | Kuan-Chen Chen Li-Jung Elizabeth Ku Ya-Hui Hu Yu Sun Alexis Elbaz Pei-Chen Lee |
| author_sort | Kuan-Chen Chen |
| collection | DOAJ |
| description | Abstract Background Parkinson’s disease (PD) exerts a considerable burden on the elderly. Studies on long-term costs for Parkinson’s disease patients in Taiwan are not available. Objectives This study aims to examine the medical resource utilization and medical costs including drug costs for PD patients in Taiwan over up to 15 years of follow-up. Methods Incident PD patients and matched non-PD subjects were identified between 2003 and 2016 from the National Health Insurance (NHI) research database. Differences in annual healthcare utilization and costs between PD and non-PD subjects from 2003 to 2018 were predicted by generalized linear models. We performed analyses stratified by PD severity and also by age, gender, and duration of follow-up. Results We identified 50,290 PD cases and 201,153 non-PD subjects. From the payer’s perspective, the average total medical costs (drug costs) associated with PD and non-PD subjects were NT$631,080 (NT$222,810) and NT$480,880 (NT$140,120), respectively. Total medical and drug costs of PD after diagnosis remained high, from NT$138,487 per patient in the first year following diagnosis up to NT$154,676 per patient at year 15. The largest components of costs were for outpatient care (55% of total medical costs), and total drugs cost (35% of total medical costs). Patients with severe PD incurred higher total medical costs compared to those with moderate or mild PD, with outpatient and inpatient costs as well as drug costs rising with disease severity. Conclusions This is the first study of its kind in Taiwan that comprehensively analyzes long-term healthcare utilization and costs among PD patients. PD imposes a significant economic burden in Taiwan, with medical (drug) costs being 1.31 (1.59) times that of non-PD individuals and costs increasing substantially with PD severity. Our findings can aid health policymakers in understanding the healthcare needs and medical costs of PD patients, supporting effective policy formulation. |
| format | Article |
| id | doaj-art-cf1e5bd518a541fbb0093a6a9ce00cc6 |
| institution | Kabale University |
| issn | 1471-2377 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Neurology |
| spelling | doaj-art-cf1e5bd518a541fbb0093a6a9ce00cc62025-01-05T12:34:09ZengBMCBMC Neurology1471-23772025-01-0125111210.1186/s12883-024-03988-3Healthcare utilization and costs for patients with Parkinson’s disease in TaiwanKuan-Chen Chen0Li-Jung Elizabeth Ku1Ya-Hui Hu2Yu Sun3Alexis Elbaz4Pei-Chen Lee5Department of Health Care Management, National Taipei University of Nursing and Health SciencesDepartment of Public Health, College of Medicine, National Cheng Kung UniversityDepartment of Public Health, College of Medicine, National Cheng Kung UniversityDepartment of Neurology, En Chu Kong HospitalUniversité Paris-Saclay, UVSQ, Gustave Roussy, Inserm, Team «Exposome, Heredity, Cancer, and Health», CESP UMR 1018Department of Public Health, College of Medicine, National Cheng Kung UniversityAbstract Background Parkinson’s disease (PD) exerts a considerable burden on the elderly. Studies on long-term costs for Parkinson’s disease patients in Taiwan are not available. Objectives This study aims to examine the medical resource utilization and medical costs including drug costs for PD patients in Taiwan over up to 15 years of follow-up. Methods Incident PD patients and matched non-PD subjects were identified between 2003 and 2016 from the National Health Insurance (NHI) research database. Differences in annual healthcare utilization and costs between PD and non-PD subjects from 2003 to 2018 were predicted by generalized linear models. We performed analyses stratified by PD severity and also by age, gender, and duration of follow-up. Results We identified 50,290 PD cases and 201,153 non-PD subjects. From the payer’s perspective, the average total medical costs (drug costs) associated with PD and non-PD subjects were NT$631,080 (NT$222,810) and NT$480,880 (NT$140,120), respectively. Total medical and drug costs of PD after diagnosis remained high, from NT$138,487 per patient in the first year following diagnosis up to NT$154,676 per patient at year 15. The largest components of costs were for outpatient care (55% of total medical costs), and total drugs cost (35% of total medical costs). Patients with severe PD incurred higher total medical costs compared to those with moderate or mild PD, with outpatient and inpatient costs as well as drug costs rising with disease severity. Conclusions This is the first study of its kind in Taiwan that comprehensively analyzes long-term healthcare utilization and costs among PD patients. PD imposes a significant economic burden in Taiwan, with medical (drug) costs being 1.31 (1.59) times that of non-PD individuals and costs increasing substantially with PD severity. Our findings can aid health policymakers in understanding the healthcare needs and medical costs of PD patients, supporting effective policy formulation.https://doi.org/10.1186/s12883-024-03988-3Parkinson’s diseaseHealthcare utilizationCostEconomic burdenNational Health Insurance |
| spellingShingle | Kuan-Chen Chen Li-Jung Elizabeth Ku Ya-Hui Hu Yu Sun Alexis Elbaz Pei-Chen Lee Healthcare utilization and costs for patients with Parkinson’s disease in Taiwan BMC Neurology Parkinson’s disease Healthcare utilization Cost Economic burden National Health Insurance |
| title | Healthcare utilization and costs for patients with Parkinson’s disease in Taiwan |
| title_full | Healthcare utilization and costs for patients with Parkinson’s disease in Taiwan |
| title_fullStr | Healthcare utilization and costs for patients with Parkinson’s disease in Taiwan |
| title_full_unstemmed | Healthcare utilization and costs for patients with Parkinson’s disease in Taiwan |
| title_short | Healthcare utilization and costs for patients with Parkinson’s disease in Taiwan |
| title_sort | healthcare utilization and costs for patients with parkinson s disease in taiwan |
| topic | Parkinson’s disease Healthcare utilization Cost Economic burden National Health Insurance |
| url | https://doi.org/10.1186/s12883-024-03988-3 |
| work_keys_str_mv | AT kuanchenchen healthcareutilizationandcostsforpatientswithparkinsonsdiseaseintaiwan AT lijungelizabethku healthcareutilizationandcostsforpatientswithparkinsonsdiseaseintaiwan AT yahuihu healthcareutilizationandcostsforpatientswithparkinsonsdiseaseintaiwan AT yusun healthcareutilizationandcostsforpatientswithparkinsonsdiseaseintaiwan AT alexiselbaz healthcareutilizationandcostsforpatientswithparkinsonsdiseaseintaiwan AT peichenlee healthcareutilizationandcostsforpatientswithparkinsonsdiseaseintaiwan |